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Rifaximin alters gut microbiota 
profile, but does not affect systemic 
inflammation - a randomized 
controlled trial in common variable 
immunodeficiency
S. F. Jørgensen1,2,3, M. E. Macpherson1,2,3, T. Bjørnetrø1,4, K. Holm1,3,4, M. Kummen1,4, 
A. Rashidi1, A. E. Michelsen1,3, T. Lekva  1, B. Halvorsen1,3, M. Trøseid1,2,3, T. E. Mollnes5,6,7, 
R. K. Berge8,9, A. Yndestad1,3, T. Ueland1,3, T. H. Karlsen1,3,4, P. Aukrust1,2,3, J. R. Hov  1,3,4 & 
B. Fevang1,2
Common variable immunodeficiency (CVID) patients have reduced gut microbial diversity compared to 
healthy controls. The reduced diversity is associated with gut leakage, increased systemic inflammation 
and ten “key” bacteria that capture the gut dysbiosis (dysbiosis index) in CVID. Rifaximin is a broad-
spectrum non-absorbable antibiotic known to reduce gut leakage (lipopolysaccharides, LPS) in liver 
disease. In this study, we explored as a ‘proof of concept’ that altering gut microbial composition 
could reduce systemic inflammation, using CVID as a disease model. Forty adult CVID patients were 
randomized, (1:1) to twice-daily oral rifaximin 550 mg versus no treatment for 2 weeks in an open-
label, single-centre study. Primary endpoints were reduction in plasma/serum levels of soluble (s) 
CD14, sCD25, sCD163, neopterin, CRP, TNF, LPS and selected cytokines measured at 0, 2 and 8 weeks. 
Secondary endpoint was changes in intra-individual bacterial diversity in stool samples. Rifaximin-
use did not significantly change any of the inflammation or gut leakage markers, but decreased gut 
microbial diversity compared with no treatment (p = 0.002). Importantly, the gut bacteria in the CVID 
dysbiosis index were not changed by rifaximin. The results suggest that modulating gut microbiota by 
rifaximin is not the chosen intervention to affect systemic inflammation, at least not in CVID.
Over the last decade, numerous discoveries have highlighted the role of gut microbiota in critical processes 
to human health including digestion, absorption of nutrients, metabolism, growth, and immune responses1. 
Compositional and functional changes of the gut microbiome, referred to as dysbiosis, have emerged as an impor-
tant contributor not only to intestinal diseases, but also systemic metabolic and inflammatory conditions such 
as obesity2, diabetes3, cardiac disease4, HIV infection5 and brain disorders1. Studies in mice have shown that 
bacteria and their products (e.g., lipopolysaccharide [LPS]) interact with the immune system both locally in 
the gut and systemically. The composition of the gut microbiota can also alter the balance between pro- and 
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anti-inflammatory immune mediators and influence important metabolic pathways, sometimes being sufficient 
to modulate disease development and progression6. However, initial gut microbiota studies in human diseases 
have been cross-sectional and not able to establish causality, i.e. in principle the dysbiosis could be entirely sec-
ondary to disease.
We have recently shown that patients with common variable immunodeficiency (CVID) display a reduced 
microbial diversity7. CVID is the most common symptomatic primary immunodeficiency among adults, charac-
terized by reduced levels of Immunoglobulin (Ig)G, IgM and/or IgA, and increased susceptibility to respiratory 
tract infections with capsulated bacteria8. Due to immune dysregulation, 74% of the patients also have one or 
more inflammatory and/or autoimmune complications, including enteropathy9,10. CVID patients have an under-
lying B-cell defect, but many patients also display T-cell dysfunction and evidence of systemic immune activation 
with elevated levels of inflammatory cytokines such as tumor necrosis factor (TNF) and interleukin (IL)-6, and 
soluble markers of monocyte/macrophage- (e.g., soluble [s]CD14) and T cell activation (i.e., sCD25)11. The reason 
for this persistent immune activation is not fully elucidated, but could at least partly reflect gut leakage mecha-
nisms with a subsequent stimulation of innate immunity through interaction with Toll like receptors (TLRs) and 
related molecules12. We have previously reported increased plasma levels of LPS in CVID patients compared to 
healthy controls, negatively correlated with gut microbial diversity7, suggesting that a less diverse gut microbiota 
is associated with increased bacterial translocation. We have therefore proposed that chronic inflammation in the 
gastrointestinal tract can cause a breach of the intestinal barrier with subsequent systemic immune activation, 
similar to what is observed in HIV infection5.
In humans, interventional studies targeting the gut microbiota could provide evidence of a causal link between 
the intestine and human disease. In the present study, we used CVID as a disease model to therapeutically manip-
ulate the gut microbiota to test our hypothesis that alteration of the microbiota affects systemic inflammation. The 
oral non-absorbable antibiotic rifaximin was chosen due to its bactericidal activity against a broad array of enteric 
pathogens and because it has been shown to reduce plasma levels of LPS in chronic liver disease with reduced risk 
of developing encephalopathy13. Importantly, there is negligible absorption of rifaximin from the gastrointestinal 
tract and thereby no direct antibacterial systemic effect which may bias the interpretation of a link between the 
gut and systemic inflammation14.
Results
All adult CVID patients (n = 124) aged 18–74 years registered at the Section of Clinical Immunology and 
Infectious Diseases at Oslo University Hospital, Rikshospitalet, Oslo, Norway were pre-screened for inclusion. 
The Section functions as a national centre for diagnosis and treatment of primary immunodeficiency diseases for 
adults in Norway, and only a few (<10) patients are followed at other hospitals in Norway. Flowchart for recruit-
ment of patients to the study is shown in Fig. 1. Out of 124 CVID patients, 11 were excluded at pre-screening 
Figure 1. Trial Profile.
www.nature.com/scientificreports/
3ScIentIfIc RepoRtS |           (2019) 9:167  | DOI:10.1038/s41598-018-35367-7
due to immunosuppressive drugs (n = 3), alcohol abuse (n = 1), type 1 diabetes (n = 2), serious multiple adverse 
reactions to antibiotics (n = 1), malignancy (n = 1), chronic herpes simplex virus infection (1) and colostomy 
(n = 2). Of the 113 CVID patients found eligible, 48 volunteered to participate in the study, and of these eight were 
not included due to recent antibiotic course (n = 6), recent probiotic use (n = 1) and lactation (n = 1). In the end 
40 patients, aged 21–69 years (63% women), with CVID were enrolled in this study and randomized to rifaximin 
550 mg bd versus no treatment for 14 days.
Baseline patient characteristics are presented in Table 1. Except for a lower frequency of patients with 
‘non-infectious complications’ in the rifaximin group (P = 0.04), there were no significant differences between 
the rifaximin and the no intervention group at baseline (Table 1).
Effect of rifaximin on markers of systemic inflammation and gut leakage. Overall there was no 
effect of rifaximin use on markers of systemic inflammation or markers of gut leakage (i.e., LPS) (uniANOVA), 
except for CRP (Table 2). The significant change in CRP was driven by an increase in CRP from baseline to week 
8 in the rifaximin group (Wilcoxon, P = 0.015) (Table 2). Furthermore, there was no effect of rifaximin treatment 
on mRNA levels of selected pro- and anti-inflammatory cytokines and chemokines in PBMC (i.e., IL-6, IL-8/
CXCL8, IL-10, IL-12, TNF, TGF-β, MIG/CXCL9, IP-10/CXCL10; Supplementary Table S1). Also, the distribu-
tion of B and T cell subpopulations, as measured by 10 readouts, remained unchanged by rifaximin use, except 








arm (n = 20) p-value*
Age mean ± SD (range) 50 ± 12 (21–69) 47 ± 11 (21–63) 53 ± 12 (21–69) 0.07
Male, n (%) 15 (38) 8 (40) 7 (35) 1.00
Immunoglobulin therapy, n (%): 0.06
   s.c.a 30 (75) 14 (70) 16 (80)
   i.v.b 6 (15) 5 (25) 1 (5)
   s.c + i.v. 4 (10) 1 (5) 3 (15)
Infection only, n (%) 8 (20) 7 (35) 1 (5) 0.04
Splenomegaly, n (%) 16 (40) 7 (35) 9 (45) 0.75
Organ-specific autoimmunity 8 (20) 5 (25) 3 (15) 0.70
Autoimmune cytopenia, n (%) 8 (20) 2 (10) 6 (30) 0.24
Enteropathy, n (%) 13 (33) 8 (40) 5 (25) 0.50
Lymphoid hyperplasia, n (%) 23 (56) 9 (45) 14 (70) 0.20
Granulomas, n (%) 6 (15) 3 (15) 3 (15) 1.00
Lymphocytic interstitial pneumonitis, n (%) 1 (2.5) 0 1(95) 1.00
Nodular regenerative hyperplasia, n (%) 1 (2.5) 0 1(95) 1.00
Overall non-infectious complications, n (%) 32 (80) 13 (65) 19 (95) 0.04
Table 1. Baseline characteristics of CVID patients in the Rifaximin study. as.c., subcutaneously; bi.v., 
intravenously. *P value for rifaximin arm compared to no-treatment arm





No Int 3.5 (2.1–7.1) 4.7 (1.0–7.9) 3.2 (2.5–6.9)
0.029
Rif 1.9 (0.86–4.80) 2.20 (1.2–4.8) 2.8 (1.9–5.4)*
sCD14
ng/mL
No Int 3949 (3162–4456) 4032 (3290–4630) 3826 (2978–4459)
0.555
Rif 3378 (3072–4219) 3639 (3241–4414) 3552 (2921–4485)
LPS
pg/ml
No Int 83 (78–91) 86 (78–92) 87 (78–94)
0.955
Rif 87 (80–96) 90 (78–98) 90 (83–102)
sCD25
ng/mL
No Int 1.44 (0.71–2.10) 1.54 (0.74–1.89) 1.33 (0.80–1.86)
0.636
Rif 0.65 (0.51–1.43) 0.63 (0.54–1.18) 0.99 (0.44–1.55)
sCD163
ng/mL
No Int 1699 (1350–2001) 1677 (984–1930) 1536 (1194–1940)
0.320
Rif 971 (647–1353) 902 (749–1310) 1151 (793–1549)
Neopterin
nmol/L
No Int 11.18 (9.40–21.60) 13.17 (8.32–24.31) 10.37 (8.11–21.90)
0.058
Rif 9.02 (6.71–14.65) 7.79 (6.37–17.24) 11.43 (6.66–21.78)
Table 2. Soluble markers of inflammation in plasma in the “rifaximin” (Rif, n = 20) and in the “no intervention” 
group (No Int, n = 20). aData are given in median (25–75 percentile). bThe p value reflects the interaction 
between time and group from UNIANOVA. *P < 0.05 vs. baseline.
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Effect of rifaximin on gut microbiota composition. In contrast to the lack of effect on markers of 
systemic inflammation, rifaximin treatment was associated with a significant change in microbial alpha diversity 
(Faith’s PD; UNIANOVA P = 0.0002, Fig. 2). Thus, there was a significant decrease in microbial alpha diversity 
(Faith’s PD: beta = −0.26, P = 0.002) after the first two weeks of the study, followed by a return to baseline six 
weeks after rifaximin was terminated (beta: 0.02 linear regression [baseline to week 8] P = 0.82, Fig. 2). Other 
measures of alpha diversity such as Chao1 (P = 0.03), Shannon index (P = 0.002) and observed OTUs (P = 0.002) 
were also significantly changed by rifaximin, whereas Simpson index (P = 0.10) was not (linear regression data 
for baseline to week 2 and baseline to week 8 are given in Supplementary Table S3). Global differences in the 
gut microbiota measured by beta diversity (i.e., to which degree different taxa are shared between individuals 
or groups of individuals) are illustrated in Fig. 3 at four time points for the two groups. The beta diversity (as 
measured by Bray-Curtis distances between paired samples at week 0 and week 2) was significantly higher in the 
rifaximin group compared to the no intervention group (Mann-Whitney P = 0.014, median 0.34 (IQR 0.32–0.40) 
and 0.27 (IQR 0.24–0.35), respectively, Fig. 4), but not between week 0 and week 8 (P = 0.46, median 0.32 (IQR 
0.28–0.36) and 0.30 (IQR 0.25–0.38), respectively).
Sixteen bacterial taxa, at different taxonomic levels, were significantly changed by rifaximin use (Table 3, 
Fig. 5). Also, the direction of change (expressed as beta values from the linear regression analysis) for the dif-
ferent taxa from baseline and week 2 and 8 are shown in Table 3. None of the ten main bacteria previously 
shown to differentiate CVID patients and healthy controls, the CVID specific dysbiosis index7, were significantly 
changed by rifaximin use (Supplementary Fig. S1), thus the CVID dysbiosis index was unchanged by rifaximin 
(Supplementary Fig. S2). Consistent with the data from our previous publication7, the dysbiosis index in the 
present study correlated with the microbial diversity (Faith’s PD) (rho = −0.42, P = 0.007, at week 0 [n = 40]), 
suggesting that the abundance of these ten bacteria captures the microbial diversity in CVID also in this study.
Adverse effects during the study. Out of 20 patients in the rifaximin group, one patient experienced 
an allergic reaction classified as a moderate adverse event. The patient stopped rifaximin immediately and was 
treated with betamethasone and the symptoms resolved after treatment. Another eight adverse events [acne 
Figure 2. Comparing alpha diversity (phylogenetic diversity [Faith’s PD]) in stool samples before (week 0), 
after (week 2) and at follow up (week 8) for a 2-week rifaximin course versus no treatment. ***P < 0.001 
(UNIANOVA, baseline values at week 0 is corrected for values at week −14 [baseline 2]).















Figure 3. Beta diversity plot with each patient’s samples at four time points for the rifaximin and no 
intervention group.
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(n = 1), nausea (n = 1), dyspepsia (n = 1), bad taste in the mouth (n = 2), abdominal pain (n = 1), loose stools 
(n = 1) and urticaria (n = 1)] were reported at the end of study visit.
Discussion
In this ‘proof of concept’ study, rifaximin had no significant effect on markers of systemic inflammation or LPS as 
a marker of gut leakage in CVID. Microbial diversity in the gut and the abundance of multiple bacteria, however, 
were changed by rifaximin, but returned to baseline after the intervention. In contrast, the previously identified 
CVID specific dysbiosis index, which has been associated with increased markers of systemic inflammation and 
gut leakage, was not affected. It could be speculated that this causes the lack of anti-inflammatory effects of rifax-
imin in these patients.
Multiple studies of rifaximin have been performed for different conditions15,16. However, the majority of these 
studies have been performed in liver diseases, where rifaximin has been convincingly shown to reduce hepatic 
encephalopathy17. Studies in cirrhotic patients with minimal encephalopathy, alcoholic cirrhosis and fatty liver 
disease have all shown reductions in LPS levels after rifaximin treatment13,18,19, also after only 2 weeks of treat-
ment as in the present study20. However, the mechanisms leading to gut leakage in severe liver failure and CVID 
may differ. In the only previous study in immunodeficient patients (i.e. HIV-infected patients), rifaximin showed 
very limited effects on neither microbial translocation nor T cell activation compared with placebo in 65 HIV 
patients, but unfortunately, this study presented no data on gut microbiota composition16.
The lack of effects observed on the primary endpoints cannot be discussed independently from the gut micro-
biota profile, where antibiotics would be expected to act. In the present study, a transient reduction of alpha 
Figure 4. Bray-Curtis distances between (paired) samples at baseline and week 2 in the rifaximin and no 
intervention group.
Figure 5. On the left are the names of the 16 taxa significantly changed by rifaximin (UNIANOVA) and on the 
right is the corresponding mean relative abundance of each specific taxa expressed (on a log2 scale) for the no 
intervention and the rifaximin group at baseline, week 2 and week 8. The colors to the left in the figure illustrate 
which taxa are in the same taxonomic family.
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diversity was observed together with changes in multiple taxa, including reduction of several Ruminococcaceae 
and increase of Bacteroides. In contrast, in a study by Ponziani et al. including 20 patients with different gastroin-
testinal and liver diseases, using 16S rRNA-based gut microbiota profiling, rifaximin increased Lactobacilli and 
decreased Roseburia, Haemophilus, Veilonella and Streptococcus. Furthermore, in two other studies including 
patients with liver cirrhosis, rifaximin use reduced Veillonellaceae21, and increased Eubacteriaceae13,21. None of 
these changes overlap with the results of the current study, but these studies did not report measures of diversity. 
One important cause of non-overlapping results could be that the effect of rifaximin depends on the initial bac-
terial composition, which probably differs between CVID and intestinal or hepatic pathologies. Random varia-
tion or methodological differences could also in part explain the lack of similarities. In addition to phenotype, 
comparability between microbiota studies can be influenced by many factors like different baseline lifestyle, diet, 
geography, host genetics, as well as lab methods including choice of PCR primers and DNA extraction22. Since all 
samples in the present study were handled exactly the same way and were sequenced in the same MiSeq run, the 
influence of methodological variation on the results should be minimal.
Several factors could potentially explain the failure of rifaximin to influence the primary end-point. In a pre-
vious study from our group, a CVID specific dysbiosis index calculated from key bacteria separated patients from 
controls7. This CVID specific dysbiosis index has been found to correlate with circulating markers of systemic 
inflammation and gut leakage, and inversely to alpha diversity. Although rifaximin reduced alpha diversity in the 
present study, there was no significant impact on the bacteria constituting the CVID specific dysbiosis index, and 
it could be hypothesized that rifaximin not targeting the putative culprits could explain the lack of effect on sys-
temic inflammation. Of particular interest would be to increase Bifidobacterium, which is reduced in CVID7, and 








No Int 0.415 (0.388–0.441) 0.385 (0.357–0.413) 0.413 (0.384–0.443)
0.012 0.28* 0.08
Rif 0.366 (0.340–0.393) 0.413 (0.385–0.441) 0.382 (0.348–0.415)
Bacteroidetes.Bacteroidia
No Int 0.414 (0.388–0.441) 0.385 (0.357–0.412) 0.413 (0.383–0.443)
0.012 0.28* 0.08
Rif 0.366 (0.340–0.393) 0.413 (0.385–0.440) 0.382 (0.348–0.415)
Bacteroidetes.Bacteroidia.Bacteroidales
No Int 0.414 (0.388–0.441) 0.385 (0.357–0.412) 0.413 (0.383–0.443)
0.012 0.28* 0.08
Rif 0.366 (0.340–0.393) 0.413 (0.385–0.440) 0.382 (0.348–0.415)
Bacteroidetes.Bacteroidia.Bacteroidales.
Bacteroidaceae
No Int 0.292 (0.267–0.316) 0.265 (0.239–0.290) 0.283 (0.255–0.310)
0.009 0.25** 0.12
Rif 0.269 (0.245–0.294) 0.315 (0.289–0.340) 0.282 (0.251–0.312)
Bacteroidetes.Bacteroidia.Bacteroidales.
Bacteroidaceae. Bacteroides
No Int 0.292 (0.267–0.316) 0.265 (0.239–0.290) 0.283 (0.255–0.310)
0.009 0.25** 0.12
Rif 0.269 (0.245–0.294) 0.315 (0.289–0.340) 0.282 (0.251–0.312)
Firmicutes.Clostridia.Clostridiales.
Family XI.Ezakiella
No Int −7.8E−20 (−1.3E−5–1.3E−5) 1.1E−5 (−2.2E−6–2.4E−5) −4.3E−7 (−1.5E−5–1.4E−5)
0.029 −0.09 0.43
Rif 5.3E−6 (−7.5 E−6–1.8E−5) 5.0E−6 (−8.3E−6–1.8 E−5) 3.4E−5 (1.8E−5–5.0E−5)
Firmicutes.Clostridia.Clostridiales.
Family XIII.Family XIII UCG-001
No Int 1.1E−4 (−3.9E−6–2.3E−4) 9.7E−5 (−2.2E−5–2.2E−4) 1.4E−4 (7.5E−6–2.6E−4)
0.028 0.04 0.15
Rif 2.3E−4 (1.2E−4–3.5E−4) 2.5E−4 (1.3E−4–3.7E−4) 0.001 (4.2E−4–0.001)
Firmicutes.Clostridia.Clostridiales.
Lachnospiraceae. Anaerostipes
No Int 3.9E−4 (−3.7E−7–0.001) 0.001 (2.5E−4–0.001) 0.001 (0.001–0.001)
0.031 0.21 −0.25
Rif 4.9E−4 (1.0E−4–0.001) 0.001 (0.001–0.002) 4.6E−4 (−3.5E−5–0.001)
Firmicutes.Clostridia.Clostridiales.
Lachnospiraceae. Lactonifactor
No Int 2.6E−5 (−9.7E−6–6.2E−5) 5.9E−5 (2.2E−5–9.6E−5) 1.2E−5 (−2.9E−5–5.2E−5)
0.0003 −0.32* 0.37*
Rif 1.0E−4 (6.4E−5–1.4E−4) 4.2E−5 (5.0E−6–8.0E−5) 1.2 E−4 (7.0E−5–1.6 E−4)
Firmicutes.Clostridia.Clostridiales.
Peptococcaceae
No Int 5.3E−5 (−1.6E−5–1.2E−4) 2.5E−5 (−4.7E−5–9.6E−5) 3.1E−6 (−7.4E−5–8.0E−5)
0.023 −0.15 0.08
Rif 2.6E−4 (1.9 E−4–3.3E−4) 5.1E−5 (−2–0E−5–1.2 E−4) 1.8 E−4 (9.6 E−5–2.7 E−4)
Firmicutes.Clostridia.Clostridiales.
Ruminococcaceae
No Int 0.003 (0.002–0.005) 0.005 (0.004–0.007) 0.003 (0.001–0.005)
0.012 −0.19 −0.01
Rif 0.007 (0.005–0.009) 0.003 (0.001–0.005) 0.006 (0.004–0.008)
Firmicutes.Clostridia.Clostridiales.
Ruminococcaceae. Anaerotruncus
No Int 0.003 (0.002–0.005) 0.005 (0.004–0.007) 0.003 (0.001–0.005)
0.013 −0.28 0.12
Rif 0.007 (0.005–0.009) 0.003 (0.001–0.005) 0.006 (0.004–0.008)
Firmicutes.Clostridia.Clostridiales.
Ruminococcaceae. Oscillibacter
No Int 1.5E−4 (6.6E−6–2.9E−4) 4.0E−4 (2.6E−4–0.001) 1.2E−4 (−3.6E−5–2.8E−4)
0.028 −0.22 0.16




No Int 0.011 (0.007–0.015) 0.017 (0.013–0.021) 0.015 (0.010–0.019)
0.014 −0.28* −0.22




No Int 0.009 (0.005–0.013) 0.011 (0.006–0.016) 0.008 (0.003–0.013)
0.018 −0.41** −0.06
Rif 0.012 (0.008–0.018) 0.001 (−0.004–0.006) 0.007 (0.002–0.013)
Firmicutes.Clostridia.Clostridiales.
Ruminococcaceae. uncultured
No Int 0.011 (0.009–0.013) 0.011 (0.009–0.013) 0.008 (0.005–0.010)
0.005 −0.08 0.28*
Rif 0.009 (0.007–0.011) 0.008 (0.001–0.006) 0.012 (0.010–0.015)
Table 3. Taxa that are significantly changed by rifaximin in stool samples from CVID patients. aData are 
given in mean (95% confidence interval). bThe p value reflects the interaction between time and group from 
UNIANOVA. cThe beta coefficient and corresponding asterisk reflects the effect of rifaximin from linear 
regression with taxa at the indicated time point as dependent and treatment and baseline taxa as independent in 
a forced model. *P < 0.05, **P < 0.01.
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that has been shown to improve gut barrier and reduce systemic LPS and inflammation in mice23. Unfortunately, 
Bifidobacterium was not increased by rifaximin in our study. Thus, although rifaximin altered alpha diversity, the 
potential “inflammatory” bacteria were not changed. However, additional studies, including intervention studies, 
are needed to causally link gut dysbiosis and systemic inflammation in CVID.
The strengths of the present study were a randomized controlled study design, which although open-label had 
blinded primary end-points. Secondly, we included both data of gut microbiota using metagenomic techniques 
and systemic inflammation, thereby expanding previous rifaximin studies in humans, irrespective of phenotype. 
The length of the intervention was an important possible limitation of the present study. Our aim was to admin-
istrate a sufficient dose and length of therapy to get the desired effect on the microbiota and at the same time 
reducing the likelihood of adverse events. Although the intervention was sufficient to induce a significant change 
in alpha- and beta diversity, and in 16 taxa, we cannot exclude that a longer intervention could result in more 
subtle changes to the gut microbial composition and levels of systemic inflammation than we were able to detect 
with a 2-week intervention. This important issue should be investigated in forthcoming studies.
The randomization of CVID patients was not stratified, and by chance, the patients randomized to rifaximin 
treatment had a smaller proportion of patients with non-infectious complications compared to the no interven-
tion group. This could imply that the rifaximin group was healthier than the no intervention group, which may 
have influenced the results. In addition, the lack of placebo excluded the use of GI symptom-questionnaire for 
evaluation of symptomatic relief with rifaximin use.
Even though the alterations in the gut microbiota induced by rifaximin did not change systemic inflamma-
tion in CVID, other interventions such as probiotics, prebiotics or fecal transplantation are likely to have differ-
ent impacts on the gut microbiota and, theoretically, systemic inflammation. There is therefore still an unused 
potential to manipulate the gut microbiota in CVID preferably targeting the ten bacteria making up the CVID 
dysbiosis index. The results herein may be of relevance to other diseases with systemic inflammation, and suggest 
that rifaximin is not the chosen intervention to affect systemic inflammation, although more data is needed to 
support this finding. In the future, other interventions should be trialled in patients with chronic systemic inflam-
mation, to further explore the ‘proof of concept’ that manipulation of the gut microbiota can influence systemic 
inflammation also in humans.
Methods
Study design and participants. We did this randomized, open, prospective, single-center, clinical trial at 
Oslo University Hospital, Rikshospitalet, Oslo, Norway between Oct 8 2013, and Oct 20, 2014. All CVID patients 
aged 18 to 74 registered at our clinic were initially pre-screened for eligibility. CVID was defined as decreased 
serum levels of IgG, IgA and/or IgM by at least two standard deviations below the mean for age, and exclusion 
of other causes of hypogammaglobulinemia24,25. Exclusion criteria were: antibiotics in the last 12 weeks, history 
of allergic reaction to rifaximin, malignancy, impaired kidney function, pregnancy or lactation, on-going infec-
tion, use of probiotics in the last 6 months, immunosuppressive drugs, comorbidity that may influence with the 
patient’s safety or compromise the study results (e.g., cardiovascular disorders, alcoholism, psychiatric disease, 
HIV infection), and polypharmacy (patient with an extensive medication list i.e. ten drugs or more). The study 
was approved by the Regional Committee for Medical and Health Research Ethics of South-Eastern Norway 
(number 2013/1037) and the Norwegian Medicines Agency (EudraCT number: 2013-000883-27), and conducted 
according to the Declaration of Helsinki. Written informed consent was obtained from all participants. The trial 
is registered with clinicaltrials.gov, number NCT01946906 (registration date 20.09.2013).
Randomization and masking. The CVID patients were randomized into two groups (rifaximin and no 
intervention) using computer-generated randomization (1:1) to receive rifaximin (Norgine, Alanno Scalo, Italy) 
or no treatment. There was no placebo drug. A statistician, not otherwise involved in the trial, generated the 
random allocation sequence. A randomization list with a combination of permuted blocks of four (n = 10) and 
blocks of two (n = 5) was generated. The sequence was concealed by using sealed envelopes containing the group 
allocation until a decision to enrol a patient was made. Due to the estimated low number of participants in 
each arm, no stratification between the two treatment arms was performed. The persons conducting the labora-
tory work related to primary and secondary endpoints were blinded to which samples were receiving the active 
treatment.
Procedures. The remaining patients after pre-screening were invited to participate in the study (see Results). 
The trial involved three outpatient visits for all patients. The patients’ eligibility to participate in the study was 
again evaluated at the first visit based on medical history, physical examination and blood tests (hematology, elec-
trolytes, kidney function tests, liver function tests, human chorion-gonadotropin in fertile women). The patients 
enrolled in the study gave baseline blood test and fecal samples at visit 1. However, 14 days before this visit a fecal 
sample was sent by post, leaving two baseline stool assessments (baseline refers to fecal samples taken at visit 1 
whereas baseline 2 refers to fecal samples taken 14 days prior to visit 1). Participants allocated to rifaximin were 
asked to take rifaximin 550 mg every 12 hours for 2 weeks, whereas the participants receiving no intervention 
were followed in the same way as the group receiving treatment. A written material containing information about 
potential adverse effects of rifaximin and contact details to the investigators in case of moderate to serious adverse 
events was handed out to the participants receiving rifaximin at visit 1.
At the second visit, the end of study visit, the participants brought a fecal sample and had blood tests taken. 
Assessment of compliance was carried out by collecting the compliance diary and counting remaining tablets in 
the box for the participants in the rifaximin group. Furthermore, the patients were assessed for the development 
of any new symptoms (blood tests and physical examination) or treatment-related adverse events. The third visit 
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at 8 weeks, follow up visit, included all the activities of the first and second visit except assessment of compliance. 
The study procedure is outlined in Fig. 6.
Primary and secondary outcome. Study endpoints were assessed at 2 weeks (i.e., study end) and at 8 
weeks (i.e. follow up). The primary endpoint was time-dependent changes in inflammatory and anti-inflammatory 
mediators and markers of gut leakage in plasma, serum and leukocytes. This included sCD14, sCD25, sCD163, 
neopterin, CRP, LPS and selected cytokines. The key secondary end points were changes in gut microbial diversity 
abundance of specific bacteria as evaluated by 16S rRNA sequencing.
Stool collection and analysis. All stool samples were collected by the participants at home with a 
standardised collection device26 and transferred to Stool Collection Tubes with Stool DNA Stabilizer (Stratec 
Biomedical, Birkenfeld, Germany)27. The first sample (2 weeks before visit 1 [baseline 2]) was returned by post 
together with a questionnaire reporting the sampling time, recent antibiotic and/or probiotic use, and medica-
tion. At visit 1 (baseline), 2 and 3, the stool samples (collected at home within the last 24 hours) were immediately 
stored at −20 °C, according to the manufacturer’s recommendation, until DNA extraction. Bacterial DNA was 
extracted using the PSP® Spin Stool DNA Plus Kit (Stratec) and subjected to high-throughput sequencing of the 
16S ribosomal RNA gene with dual-indexed barcodes according to an established protocol, followed by sequenc-
ing on an Illumina MiSeq (Supplementary Methods)28.
Differences in microbial composition between groups were evaluated by measures of alpha diversity (within 
sample bacterial diversity), beta diversity (between sample bacterial diversity), dysbiosis index and the relative 
abundance of individual taxa (Supplementary Methods).
CVID dysbiosis index. We have previously published a specific CVID dysbiosis index that consists of the 
relative abundance of ten bacteria at different taxonomic levels, which captured the change in alpha diversity 
between CVID and healthy controls7. We, therefore, calculated the dysbiosis index for all samples at all four 
time points using the formula: Loge [(sum of the relative abundances of bacteria increased in CVID)/(sum of 
the relative abundances of bacteria reduced in CVID)]. Bacteria which are increased in CVID include Bacilli, 
Dorea, Roseburia, Gammaproteobacteria and bacteria which are reduced in CVID include Bifidobacterium, 
Odoribacteracea, Christensenellaceae, Blautia, Sutterella, Desulfovibrionace7.
Blood sampling protocol. Peripheral venous blood was drawn into sterile blood collection tubes without 
any additives (serum) or with EDTA as anticoagulant (plasma). The tubes were immediately immersed in melt-
ing ice, centrifuged within 15 minutes at 2000g for 20 minutes to obtain platelet-poor plasma or were allowed to 
clot at room temperature before centrifugation at 1000 g for 10 minutes (serum). Plasma and serum were stored 
at −80 °C in aliquots and thawed only once. Peripheral blood mononuclear cells (PBMC) were isolated from 
heparinised venous blood isolated by gradient centrifugation using Lymphoprep (Axis Shield, Oslo, Norway) 
within 1 hour after blood collection and PBMC pellets were immediately stored at −80 °C until mRNA analyses 
(Supplementary Methods).
Measurements of inflammatory and gut leakage markers. Serum levels of sCD14, neopterin, 
sCD163 and sCD25 were quantified in duplicate by enzyme immunoassays obtained from R&D Systems 
(Minneapolis, MN). LPS was analysed by Limulus Amebocyte Lysate chromogenic assay (Lonza, Walkersville, 
MD) according to the manufacturer’s instructions, with the following modifications: Samples were diluted 5-fold 
to avoid interference with background colour, and preheated to 67 °C for 12 minutes prior to analysis to dissolve 
immune complexes. Serum levels of CRP were sampled together with safety blood samples via the routine hospi-
tal laboratory. B- and T-cell subpopulations were analysed by flow cytometry (Supplementary Methods).
Subgroup analysis. Clinical subgroups were classified as “Infection only” or “Complications” based on 
previously defined criteria9 with one modification; CVID enteropathy was defined as persistent diarrhea after 
exclusion of gastrointestinal infection.
Statistical analysis. The primary objective of the statistical analysis was to compare the effect of rifaximin 
therapy with no therapy on gut leakage and inflammatory markers. This was an explorative study and we found 
that strict samples size calculation was inappropriate. However, we estimated an approximate 50% difference in 
changes in inflammatory markers between the two groups, and with 25 patients in each group we would have 
95% power to detect a 50% (0.75) difference with an alpha of 0.05. Since CVID is a rare disease, we were only able 
Figure 6. The study procedure.
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to recruit 20 patients in each group. Univariate Repeated measures ANOVA (UNIANOVA) was used to assess 
the effect of treatment focusing on the interaction between time and treatment group for the different markers, 
followed by paired samples t-test or Wilcoxon’s Rank-Sum test for paired data if significant. Skewed variables were 
log transformed prior to regression analysis.
Differences in microbial composition between groups were evaluated by measures of alpha diversity (within 
individual bacterial richness), dysbiosis index and the abundance of individual taxa. Also, for alpha diversity, 
dysbiosis index and taxa UNIANOVA was used ‘a priori’. For the significant taxa, linear regression was performed 
with taxa at 2 or 8 weeks as dependent and baseline taxa and treatment group as independent variables in a forced 
model. When not specified otherwise, statistical analyses were performed with SPSS (IBM, Armonk, NY, USA). 
P values were two-sided and considered significant when <0.05.
Data Availability
The datasets generated during and/or analyzed during the current study are not publicly available due to Nor-
wegian legislation about general data protection regulation, but are available from the corresponding author on 
reasonable request.
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